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Hyperbilirubinemia of the Newborn
David Schutzman, MD
7/16/2020
Kernicterus
• Classic Kernicterus
• Phase 1 – lethargy, hypotonia, poor feeds
• Phase 2 – hypertonia, high pitched cry
• Phase 3 – hypotonia
• Long term – chorioathetoid CP, hearing loss, normal intelligence
• Histology – neuronal necrosis
• NICU kernicterus
• No symptomatology
• “Normal” bilirubin levels
• Histology – spongy changes and gliosis
How do we get kernicterus?

How does bilirubin enter the brain?
Blood Brain Barrier
• Keeps things out of the brain
• Endothelial lining of the blood vessels
• Excludes most water soluble substances
• Proteins
• Large molecules
• Albumin
• Albumin with bilirubin attached
• Allows in lipid soluble substances
• Free bilirubin
• Large complexes enter if the barrier is opened
Free bilirubin hypothesis
• Bilirubin insoluble at pH 7.4
• Normally bound to albumin in the blood
• Albumin – one high affinity site
• ≥ one weak affinity sites
• Bilirubin:albumin molar ratio 1:1
• 1 g albumin binds 8.8 mg bilirubin (if high affinity site completely saturated)
• Term – 3.5 g albumin with 1:1 binding affinity
• Bili level 31.1 before free bilirubin available
• Preterm – 2 g albumin with only 0.5 binding affinity
• Bili level 8.9 before free bilirubin available
Displacers of bilirubin
• Free fatty acids – Intralipid
• Drugs
• Sulfisoxasole
• Benzyl alcohol
• pH
Factors that open the BBB
• Hypertonic solutions
• Levine’s rat studies
• Severe asphyxia
• Acidosis
• Meningitis

How does bilirubin cause damage?
• WE DON’T KNOW
• Depress cellular respiration
• Uncouple oxidative phosphorylation
• Bind specific proteins
• Damage DNA
How do we prevent kernicterus?
Exchange transfusion
• Last resort
• Very invasive
• Double volume exchange
• Insert central lines
• Remove and replace aliquots of 1/15 baby’s blood volume with O- PRBC 
reconstituted with AB FFP
• Repeat (again and again) until replace what’s calculated to be twice baby’s 
blood volume
• y=1-𝑒−𝑥
• y-fraction of blood removed   x-number of exchanges
• Single volume exchange replaces 63% of blood volume
• Double volume exchange replaces 87% of blood volume
• Removes actual circulating bilirubin
• Removes potential bilirubin
Hsia, DY, Allen FH, Gellis SS, et.al. Erythroblastosis fetalis VIII. 
Studies of serum bilirubin in relation to kernicterus                                               
NEJM 1952;247:668
• Retrospective study 
• Bilirubin 16-30     18% kernicterus
• Bilirubin >30         50% kernicterus
• Recommended keeping bilirubin <20
• No kernicterus in their subsequent 200 consecutive cases of 
erythroblastosis
• Accumulated these patients in <1 year!
Phototherapy
How does phototherapy work?


“What did he know and when did he 
know it?”
What do we do and when do we do it?


Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin 
for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics 
1999;103:6-14.
Bhutani Nomogram
• 13,003 healthy term and near term 
• Screening TSB at time of newborn screen with age in hours determined
• Racially diverse
• 60% breast fed
• Exclusions
• Phototherapy before 60 hours of life
• Hemolysis indicated by DAT+
• 2840 in hospital supervised F/U program

Results of Bhutani nomogram for daily practice
• Zone 1 – no F/U needed
• Zone 2 – F/U bilirubin in 48 hours
• Zone 3 – F/U bilirubin in 24 hours
• Zone 4 – consider phototherapy
Hour-Specific Bilirubin Nomogram in Infants with ABO 
Incompatibility and Direct Coombs-Positive Results.
Schutzman DL, Sekhon R, Hundalani S. Arch Pediatr Adolesc Med 2010;164:1158-1164
• 700 babies ≥ 35 weeks gestation
• 460 DAT neg
• 240 DAT+
• Age specific screening bilirubins plotted on Bhutani nomogram
• Sensitivity and specificity for infants in zone 4 or zone 3 &4 combined similar 
to Bhutani
• LR zone 4 twice Bhutani’s
• All infants zone 3 and 4 followed post D/C
• No XT or bilirubin encephalopathy
• Bhutani nomogram works equally well for F/U of DAT+ infants
Management of hyperbilirubinemia in the newborn infant 35 or more weeks of 
gestation. AAP Subcommittee on Hyperbilirubinemia. Pediatrics 2004;114:304
Guidelines for exchange transfusion in infants 35 or more weeks gestation . 
AAP Subcommittee on Hyperbilirubinemia. Pediatrics 2004;114:304
Adjustments to AAP recommendations
Risk factors
• Use total bilirubin – do not subtract direct fraction
• Risk factors
• Isoimmune hemolytic disease
• G6PD deficiency
• Asphyxia
• Significant lethargy
• Temperature instability
• Sepsis
• Acidosis
• Albumin <3 g/dL (if measured)
Isoimmune Hemolytic Disease
• Variability in need for phototherapy in DAT+ infants
• Schutzman, et.al. Arch Pediatr Adolesc Med 2010;164:1158-1164
• African American cohort
• 12.9 % DAT+ infants required phototherapy
• Kaplan, et.al. E-PAS 2008:635841.21
• Israeli Sephardi cohort
• 49% DAT+ infants required phototherapy
• Sarici, et. al. Pediatrics 2002;109:e53-e58
• Italian cohort
• 100% DAT+ infants required phototherapy
TABLE 2. Risk Factors for Development of Severe Hyperbilirubinemia 
in Infants of 35 or More Weeks’ Gestation (in Approximate 
Order of Importance) 
Major risk factors 
Predischarge TSB or TcB level in the high-risk zone (Fig 2)25,31 
Jaundice observed in the first 24 h30 
Blood group incompatibility with positive direct antiglobulin 
test, other known hemolytic disease (eg, G6PD deficiency), 
elevated ETCOc 
Gestational age 35–36 wk39,40 
Previous sibling received phototherapy40,41 
Cephalohematoma or significant bruising39 
Exclusive breastfeeding, particularly if nursing is not going 
well and weight loss is excessive39,40 
East Asian race39* 
Minor risk factors 
Predischarge TSB or TcB level in the high intermediate-risk 
zone25,31 
Gestational age 37–38 wk39,40 
Jaundice observed before discharge40 
Previous sibling with jaundice40,41 
Macrosomic infant of a diabetic mother42,43 
Maternal age _25 y39 
Male gender39,40 
Decreased risk (these factors are associated with decreased risk of 
significant jaundice, listed in order of decreasing importance) 
TSB or TcB level in the low-risk zone (Fig 2)25,31 
Gestational age _41 wk39 
Exclusive bottle feeding39,40 
Black race38* 
Discharge from hospital after 72 h40,44 
* Race as defined by mother’s description. 
• AAP Clinical Practice Guideline 2004
• Blood group incompatibility with DAT+ a major risk factor for severe hyperbili
• No reference given
CO - a better measure of hemolysis and hence risk
(Not yet endorsed by the AAP or necessarily agreed to by the Bilirubin club at PAS)
How can we measure CO in the body?
• Schutzman, et. al.  J Perinatology 2016:36:386-388
• 180 AA infants
• All mothers O+
• 60 O+   60 ABO/DAT neg 60 ABO/DAT+
• Mean COHbc in O+ and ABO/DAT neg 0.77±0.23%
• 2SD > mean 1.22%
• 15/60 DAT+ >1.22%
• 4/120 DAT neg >1.22%
Capnia CoSense Monitor –End Tidal CO  (ETCO)

What is a normal ETCOc?
• Christensen, et. al. Neonatology 2016;109:1-5
• 100 infants Intermountain Health Group  
• Caucasian 76%  Non-Caucasian 24%
• ETCO 95%  >2.0ppm
• Bhutani, Maisels, Schutzman, et. al. Acta Paediatr. 2018        
Aug;107(8):1350-1356
• 247 infants
• Caucasian 46%   African American 23%    Asian 10%   Hispanic 18%
• ETCO 90%  >2.0ppm
• ETCO 95%  >2.5ppm
Why Use ETCO rather than DAT
• ElSaie, Taleb, Nicosia, Zangaladze, Pease, Newton, Schutzman in 
submission
• 191 babies with DAT+ or ETCO for HIR or HR zones
• Theoretical decision to use photo or not based on AAP 
recommendations and using DAT OR ETCO to delineate hemolysis
• 27% of DAT+ actually hemolyzing per ETCO
• 29% of DAT neg actually hemolyzing per ETCO
• Management of 9.4% differed if used ETCO instead of DAT
• 8 fewer babies would have received photo using ETCO
All infants  Gestational Age  ≥ 35 weeks 
Transcutaneous Bilirubin (TcBili) on discharge day (@ midnight  to 0400 AM)
Refer to Table 1 to assess need for Total Serum Bili (TSB)
TSB Not indicated 
Low Risk zone Low Intermediate Zone
TSB check in 48 hrs   
with  PCP f/up in 3 days
Follow-up PCP 
TSB indicated
TSB Low Risk Zone or 
Low intermediate zone
Follow pathway on the  left
TSB High intermediate zone
TSB High risk zone
ETCO
Follow AAP phototherapy* 
parameter
<1.6 ppm ≥ 2.5  ppm (moves 
infant to next higher 
risk category in AAP 
parameter )
1. 6 - 2.4 ppm
Assess Risk Factors 
(Table 2)
Discharge with TSB in  24 hrs
No Yes
Repeat TSB 6-8 hrs
Follow AAP phototherapy*
parameter or Hour-specific Bilirubin 
Normogram
TN Bilirubin Guideline 
Page 1
Table 2. RISK FACTORS FOR 
HYPERBILIRUBINEMIA IN 
NEWBORN NURSERY
Jaundice before 24 hours
Direct Coombs +
Late preterm
Previous sibling received 
phototherapy
Cephalhematoma or significant 
bruising
Excessive weight loss 
East Asian race
*TSB follow-up when 
phototherapy started
Table 1. INDICATIONS FOR SERUM 
BILIRUBIN
Age in Hours TcBili
< 20 ≥ 5
21-24 ≥ 6
25-27 ≥ 6.5
28-31 ≥ 7
32-36 ≥ 8
37-40 ≥ 9
41-45 ≥ 10
46-49 ≥ 10.5
50-55 ≥ 11
>55 ≥ 12
*If started on Phototherapy:
1. Obtain  Hgb/Hct, Reticulocyte.
2. If suspect dehydration and/or exclusive 
breast feeding, obtain BMP.
3. If ABO set-up, may repeat Type and 
Coombs if initially negative.
Revised 10/17/2019
Infant DAT or Direct Coombs + Gestational Age  ≥ 35 weeks 
TcBili, Hgb/Hct, Reticulocyte @ 12 hrs 
TcBili Low Risk zone or 
Low Intermediate zone
TCBili High Intermediate 
zone
TcBili High Risk Zone
ETCO@ 12-24 hrsETCO@ 12-24 hrs
<1.6 ppm 1.6-2.4 ppm ≥ 2.5 ppm <1.6 ppm 1.6-2.4 ppm
≥ 2.5 ppm ( moves  infant to next 
higher risk category in AAP 
parameter)
TcBili on d/c day TSB Q 24 hrs TSB Q 8 hrs TSB Q 24 hrs TSB Q 12 hrs TSB Q 8 hrs
Follow AAP phototherapy* 
parameter
TN Bilirubin Guideline 
Page 2
Refer to TN Bili 
Guideline page 1
*TSB follow-up when 
phototherapy started
Follow AAP phototherapy* 
parameter or Hour-specific 
Bilirubin Normogram
Revised 10/17/2019
BILITOOL.ORG
option one 
 
Date and time of birth to closest hour: 
   
2020
             
July
 |                                
14
                         
 
Date and time of blood sampling to closest hour: 
   
2020
             
July
 |                                
15
                         
 
Total Bilirubin*: 
     
mg/dl (US)
 
Submit
 
 
 
option two 
Age (hours):  (12-146 hours) 
Total Bilirubin*: 
     
mg/dl (US)
 
Submit
 
*Note: The default unit of measure for total bilirubin is mg/dl. Please select µmol/L if your bilirubin 
values are captured in the global standard SI metric units. Bilirubin conversion from US to SI units is 
17.1. 
Results are based on the Hour-Specific Nomogram for Risk Stratification published in "Management of 
Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation" (2004) by the AAP journal. 
 
Hour-Specific Nomogram for Risk Stratification 
Infant age 36 hours  
Total bilirubin 10.7 mg/dl  
Risk zone High Intermediate Risk  
Risk zone is one of several risk factors for developing severe hyperbilirubinemia. 
Recommended Follow-up 
Hyperbili Risk Level Interval 
Lower Risk 
(>= 38 weeks and well) 
Follow-up within 48 hours and consider TcB/TSB at follow-
up 
Medium Risk 
(>=38 weeks + hyperbili risk factors OR 35 to 37 6/7 
weeks and well) 
Evaluate for phototherapy and check TcB/TSB within 24 
hours 
Higher Risk 
(35 to 37 6/7 weeks and hyperbili risk factors) 
Evaluate for phototherapy and check TcB/TSB in 4-24 
hours 
    
AAP Phototherapy Guidelines (2004) 
Neurotoxicity Risk Level Start phototherapy? 
Approximate threshold at 
36 hours of age 
Lower Risk 
(>= 38 weeks and well) 
No 13.6 mg/dl 
Medium Risk 
(>=38 weeks + neurotoxicity risk factors OR 35 to 37 6/7 
weeks and well) 
No 11.7 mg/dl 
Higher Risk 
(35 to 37 6/7 weeks and neurotoxicity risk factors) 
Yes 9.6 mg/dl 
It is an option to provide conventional phototherapy in the hospital or at home at TSB levels 2-3 
mg/dl (35-50 µmol/L) below those shown. Home phototherapy should not be used in infants with risk 
factors. 
If phototherapy threshold is exceeded, please also review AAP Guidelines for Exchange Transfusion. 
 
The Curious Case of the Missing Bilirubin

• Full term female born by SVD
• Mother O+
• Infant O+ DAT+
• Mother anti c +
• Titer <1:1   2 months PTD
• Titer 1:32 2 weeks PTD
• Infant labs
• H/H 11.3/34.1
• Reticulocytes 17.7%
• ETCO 6.8 PPM (>>>95%)
• Tcbili @33 hr 3.9
• TSB @48 hr 4.1
• TSB@61 hr 6.0
• HO-1 promoter variant (GT)n repeats  
• 23 and 30 repeats for the two alleles
• Long repeats (>33) would have decreased function
• SLCO1B1 transporter 
• Heterozygous *5 (c.521C>T)
• No effect
• UGT1A1 
• Homozygous *60 (c.3275T>G)  may be associated with decreased function
• Heterozygous *89 (c.3436C>A)  no effect
• Heterozygous *66/*88 (c.997-82C>T)  possible decreased activity due to 
compound heterozygote
• NO TA5 repeat in promoter region which ENHANCES activity

